By determining the BRAF gene status on EVs from plasma samples of metastatic melanoma patients at the beginning and during therapy with BRAF inhibitors, Zocco and collaborators showed that EV-associated DNA can be a better alternative to ctDNA for detection of mutant BRAF in these patients (Zocco et al., 2020). This evidence concerns the gene BRAF and metastatic melanoma.